Dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats: Role of the brain angiotensin system

Brain

Volumn 135, Issue 1, 2012, Pages 124-138

  Rodriguez Perez, Ana I ^a,b   Valenzuela, Rita ^a,b   Villar Cheda, Begoña ^a,b   Guerra, Maria J ^a,b   Labandeira Garcia, Jose L ^a,b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

ageing; angiotensin; menopause; oestrogen; Parkinson's disease

Indexed keywords

ANDROGEN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; CANDESARTAN; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE; ESTRADIOL; ESTRADIOL BENZOATE; INTERLEUKIN 1BETA; OXIDOPAMINE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANDROGEN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; CELL LOSS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; MENOPAUSE; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT DURATION;

EID: 84856748705     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awr320     Document Type: Article

References (97)

1. Andersen JK. Oxidative stress in neurodegeneration: cause or consequence. Nat Med 2004; 10: S18-25. (Pubitemid 38901863)
2. Antonicelli R, Olivieri F, Morichi V, Urbani E, Mais V. Prevention of cardiovascular events in early menopause: a possible role for hormone replacement therapy. Int J Cardiol 2008; 130: 140-6.
3. Armando I, Jezova M, Juorio AV, Terró n JA, Falcó n-Neri A, et al. Estrogen upregulates renal angiotensin II AT(2) receptors. Am J Physiol Renal Physiol 2002; 283: F934-43. (Pubitemid 35192459)
4. Babior B. NADPH oxidase: an update. Blood 1999; 93: 1464-76. (Pubitemid 29102471)
5. Babior BM. NADPH oxidase. Curr Opin Immunol 2004; 16: 42-7. (Pubitemid 38198116)
6. Bake S, Ma L, Sohrabji F. Estrogen receptor-alpha overexpression suppresses 17beta-estradiol-mediated vascular endothelial growth factor expression and activation of survival kinases. Endocrinology 2008; 149: 3881-9.
7. Basso N, Paglia N, Stella I, de Cavanagh EM, Ferder L, del Rosario Lores Arnaiz M, et al. Protective effect of the inhibition of the renin-angiotensin system on aging. Regul Pept 2005; 128: 247-52. (Pubitemid 40544840)
8. Becker JB. Gender differences in dopaminergic function in striatum and nucleus accumbens. Pharmacol Biochem Behav 1999; 64: 803-12.
9. Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, et al. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest 2009; 119: 524-30.
10. Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 2003; 24: 471-8. (Pubitemid 37088172)
11. Chakrabarty A, Blacklock A, Svojanovsky S, Smith PG. Estrogen elicits dorsal root ganglion axon sprouting via a renin-angiotensin system. Endocrinology 2008; 149: 3452-60. (Pubitemid 351919601)
12. Chen J, Yang S, Hu S, Choudhry MA, Bland KI, Chaudry IH. Estrogen prevents intestinal inflammation after trauma-hemorrhage via downregulation of angiotensin II and angiotensin II subtype I receptor. Am J Physiol Gastrointest Liver Physiol 2008; 295: G1131-7.
13. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010; 304: 1684-92.
14. Choi DY, Zhang J, Bing G. Aging enhances the neuroinflammatory response and alpha-synuclein nitration in rats. Neurobiol Aging 2010; 31: 1649-53.
15. Clarkson TB. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause 2007; 14: 373-84.
16. Clarkson TB, Appt SE. Controversies about HRT-lessons from monkey models. Maturitas 2005; 51: 64-74.
17. Clarkson TB, Mehaffey MH. Coronary heart disease of females: lessons learned from nonhuman primates. Am J Primatol 2009; 71: 785-93.
18. Cruz-Muros I, Afonso-Oramas D, Abreu P, Pérez-Delgado MM, Rodŕiguez M, González-Hernández T. Aging effects on the dopamine transporter expression and compensatory mechanisms. Neurobiol Aging 2009; 30: 973-86.
19. Csiszar A, Ungvari Z, Koller A, Edwards JG, Kaley G. Aging-induced proinflammatory shift in cytokine expression profile in coronary arteries. FASEB J 2003; 17: 1183-5.
20. Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF. Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol 2004; 61: 886-8. (Pubitemid 38747327)
21. Dean SA, Tan J, O'Brien ER, Leenen FH. 17beta-estradiol downregulates tissue angiotensin-converting enzyme and ANG II type 1 receptor in female rats. Am J Physiol Regul Integr Comp Physiol 2004; 288: R759-66. (Pubitemid 40250590)
22. Dluzen D. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine. Brain Res 1997; 767: 340-4. (Pubitemid 27435781)
23. Dziuk PJ, Cook B. Passage of steroids through silicone rubber. Endocrinology 1966; 78: 208-11.
24. Febo M, Ferris CF, Segarra AC. Estrogen influences cocaine-induced blood oxygen level-dependent signal changes in female rats. J Neurosci 2005; 25: 1132-6. (Pubitemid 40268954)
25. Febo M, Jiménez-Rivera CA, Segarra AC. Estrogen and opioids interact to modulate the locomotor response to cocaine in the female rat. Brain Res 2002; 943: 151-61. (Pubitemid 34671183)
26. Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res 2002; 53: 672-7. (Pubitemid 34175260)
27. Fogle RH, Stanczyk FZ, Zhang X, Paulson RJ. Ovarian androgen production in postmenopausal women. J Clin Endocrinol Metab 2007; 92: 3040-3. (Pubitemid 47236368)
28. Gao HM, Liu B, Zhang W, Hong JS. Synergistic dopaminergic neurotox-icity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. FASEB J 2003; 17: 1957-9.
29. Gildea JJ. Dopamine and angiotensin as renal counterregulatory systems controlling sodium balance. Curr Opin Nephrol Hypertens 2009; 18: 28-32.
30. Gundersen HJG. Bendsen, T.F., Korbo, L., Marcussen, N., Moller, A., Nielsen, K., Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APIMS 1988; 96: 379-94.
31. Harman SM, Naftolin F, Brinton EA, Judelson DR. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence. Ann NY Acad Sci 2005; 1052: 43-56. (Pubitemid 41338957)
32. Hemming ML, Selkoe DJ, Farris W. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid b-protein metabolism in mouse models of Alzheimer disease. Neurobiol Dis 2007; 26: 273-81. (Pubitemid 46436503)
33. Henriques T, Zhang X, Yiannikouris FB, Daugherty A, Cassis LA. Androgen increases AT1a receptor expression in abdominal aortas to promote angiotensin II-induced AAAs in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2008; 28: 1251-6.
34. Heymes C, Silvestre JS, Llorens-Cortes C, Chevalier B, Marotte F, Levy BI, et al. Cardiac senescence is associated with enhanced expression of angiotensin II receptor subtypes. Endocrinology 1998; 139: 2579-87. (Pubitemid 28513788)
35. Hoshi-Fukushima R, Nakamoto H, Imai H, Kanno Y, Ishida Y, Yamanouchi Y, et al. Estrogen and angiotensin II interactions determine cardio-renal damage in Dahl salt-sensitive rats with heart failure. Am J Nephrol 2008; 28: 413-23. (Pubitemid 351501607)
36. Imanishi T, Hano T, Nishio I. Estrogen reduces angiotensin II-induced acceleration of senescence in endothelial progenitor cells. Hypertens Res 2005; 28: 263-71. (Pubitemid 40812612)
37. Joglar B, Rodriguez-Pallares J, Rodríguez-Perez AI, Rey P, Guerra MJ, Labandeira-Garcia JL. The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. J Neurochem 2009; 109: 656-69.
38. Johnson AB, Bake S, Lewis DK, Sohrabji F. Temporal expression of IL-1beta protein and mRNA in the brain after systemic LPS injection is affected by age and estrogen. J Neuroimmunol 2006; 174: 82-91.
39. Kondo T, Yoshida K, Yoshimura Y, Motohashi M, Tanayama S. Disposition of the new angiotensin II receptor antagonist candesartan cilexetil in rats and dogs. Arzneimittelforschung 1996; 46: 594-600. (Pubitemid 26201370)
40. Korse CM, Bonfrer JM, van Beurden M, Verheijen RH, Rookus MA. Estradiol and testosterone levels are lower after oophorectomy than after natural menopause. Tumour Biol 2009; 30: 37-42.
41. Krishnamurthi K, Verbalis JG, Zheng W, Wu Z, Clerch LB, Sandberg K. Estrogen regulates angiotensin AT1 receptor expression via cytosolic proteins that bind to the 5 leader sequence of the receptor mRNA. Endocrinology 1999; 140: 5435-8.
42. Li JM, Shah AM. Mechanism of endothelial cell NADPH oxidase activation by angiotensin II. Role of the p47phox subunit. J Biol Chem 2003; 278: 12094-100. (Pubitemid 36800187)
43. Liu B, Dluzen DE. Oestrogen and nigrostriatal dopaminergic neurodegen-eration: animal models and clinical reports of Parkinson's disease. Clin Exp Pharmacol Physiol 2007; 34: 555-65. (Pubitemid 46953100)
44. Liu HW, Iwai M, Takeda-Matsubara Y, Wu L, Li JM, Okumura M, et al. Effect of estrogen and AT1 receptor blocker on neointima formation. Hypertension 2002; 40: 451-7.
45. Mannino CA, South SM, Inturrisi CE, Quinones-Jenab V. Pharmacokinetics and effects of 17beta-estradiol and progesterone implants in ovariectomized rats. J Pain 2005; 6: 809-16. (Pubitemid 41739598)
46. McCormack AL, Di Monte DA, Delfani K, Irwin I, DeLanney LE, Langston WJ, et al. Aging of the nigrostriatal system in the squirrel monkey. J Comp Neurol 2004; 471: 387-95. (Pubitemid 38401739)
47. McKinley MJ, Albiston AL, Allen AM, Mathai ML, May CN, McAllen RM, et al. The brain reenin-angiotensin system: location and physiological roles. Int J Biochem Cell Biol 2003; 35: 901-18. (Pubitemid 36379330)
48. Miller VM, Black DM, Brinton EA, Budoff MJ, Cedars MI, Hodis HN, et al. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res 2009; 2: 228-39.
49. Miller VM, Clarkson TB, Harman SM, Brinton EA, Cedars M, Lobo R, et al. Women, hormones, and clinical trials: a beginning, not an end. J Appl Physiol 2005; 99: 381-3. (Pubitemid 41061128)
50. Morale MC, Serra PA, L'episcopo F, Tirolo C, Caniglia S, Testa N, et al. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration. Neuroscience 2006; 138: 869-78.
51. Murray HE, Pillai AV, McArthur SR, Razvi N, Datla KP, Dexter DT, Gillies GE. Dose-and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females. Neuroscience 2003; 116: 213-22. (Pubitemid 36110447)
52. Nequin LG, Alvarez J, Schwartz NB. Measurement of serum steroid and gonadotropin levels and uterin and ovarian variables throughout 4-day and 5-day estrous cycles in the rat. Biol Reprod 1979; 20: 659-70. (Pubitemid 9156442)
53. Nickenig G, Bäumer AT, Grohè C, Kahlert S, Strehlow K, Rosenkranz S, et al. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation 1998; 97: 2197-201. (Pubitemid 28265380)
54. Nogawa N, Sumino H, Ichikawa S, Kumakura H, Takayama Y, Nakamura T, et al. Effect of long-term hormone replacement therapy on angiotensin-converting enzyme activity and bradykinin in postme-nopausal women with essential hypertension and normotensive post-menopausal women. Menopause 2001; 8: 210-5. (Pubitemid 32410994)
55. Ohtani H, Nomoto M, Douchi T. Chronic estrogen treatment replaces striatal dopaminergic function in ovariectomized rats. Brain Res 2001; 900: 163-8. (Pubitemid 32382108)
56. Ojeda NB, Royals TP, Black JT, Dasinger JH, Johnson JM, Alexander BT. Enhanced sensitivity to acute angiotensin II is testosterone dependent in adult male growth-restricted offspring. Am J Physiol Regul Integr Comp Physiol 2010; 298: R1421-7.
57. Okumura M, Iwai M, Ide A, Mogi M, Ito M, Horiuchi M. Sex difference in vascular injury and the vasoprotective effect of valsartan are related to differential AT2 receptor expression. Hypertension 2005; 46: 577-83. (Pubitemid 41376840)
58. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. New York: Academic Press; 1985.
59. Przedborski S, Levivier M, Jiang H, Ferreira M, Jackson-Lewis V, Donaldson D, et al. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 1995; 67: 631-47.
60. Qin L, Liu Y, Wang T, Wei SJ, Block ML, Wilson B, et al. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflamma-tory gene expression in activated microglia. J Biol Chem 2004; 279: 1415-21. (Pubitemid 38082669)
61. Ragonese P, D'Amelio M, Callari G, Salemi G, Morgante L, Savettieri G. Age at menopause predicts age at onset of Parkinson's disease. Mov Disord 2006a; 21: 2211-4. (Pubitemid 46140440)
62. Ragonese P, D'Amelio M, Savettieri G. Implications for estrogens in Parkinson's disease: an epidemiological approach. Ann NY Acad Sci 2006b; 1089: 373-82. (Pubitemid 47092059)
63. Rey P, Lopez-Real A, Sanchez-Iglesias, Muñoz A, Soto-Otero R, Labandeira-Garcia JL. Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons. Neurobiol Aging 2007; 28: 555-67. (Pubitemid 46282209)
64. Rodriguez-Pallares J, Parga JA, Muñoz A, Rey P, Guerra MJ, Labandeira-Garcia JL. Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons. J Neurochem 2007; 103: 145-56. (Pubitemid 47404195)
65. Rodriguez-Pallares J, Rey P, Parga JA, Muñoz A, Guerra MJ, Labandeira-Garcia JL. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol Dis 2008; 31: 58-73.
66. Rodriguez-Perez AI, Valenzuela R, Villar-Cheda B, Guerra MJ, Lanciego JL, Labandeira-Garcia JL. Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson's diseas. Exp Neurol 2010; 224: 517-26.
67. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33. (Pubitemid 34761611)
68. Rueckschloss U, Quinn MT, Holtz J, Morawietz H. Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2002; 22: 1845-51. (Pubitemid 35315771)
69. Saavedra JM. Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities. Cell Mol Neurobiol 2005; 25: 485-12.
70. Sakata A, Mogi M, Iwanami J, Tsukuda K, Min LJ, Fujita T, et al. Sex-different effect of angiotensin II type 2 receptor on ischemic brain injury and cognitive function. Brain Res 2009; 1300: 14-23.
71. Sandoval KE, Witt KA. Age and 17b-estradiol effects on blood-brain barrier tight junction and estrogen receptor proteins in ovariectomized rats. Microvascular Research 2011; 81: 198-205.
72. Sauer H, Oertel WH. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunohis-tochemical study in the rat. Neuroscience 1994; 59: 401-15. (Pubitemid 24098798)
73. Selvamani A, Sohrabji F. Reproductive age modulates the impact of focal ischemia on the forebrain as well as the effects of estrogen treatment in female rats. Neurobiol Aging 2010; 31: 1618-28.
74. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 2002; 91: 406-13. (Pubitemid 35034208)
75. Shulman LM. Is there a connection between estrogen and Parkinson's disease? Parkinsonism Relat Disord 2002; 8: 289-95. (Pubitemid 34520453)
76. Sohn HY, Raff U, Hoffmann A, Gloe T, Heermeier K, Galle J, et al. Differential role of angiotensin II receptor subtypes on endothelial superoxide formation. Br J Pharmacol 2000; 131: 667-72.
77. Sohrabji F, Bake S. Age-related changes in neuroprotection: is estrogen pro-inflammatory for the reproductive senescent brain? Endocrine 2006; 29: 191-7. (Pubitemid 44097362)
78. Sohrabji F. Estrogen: a neuroprotective or proinflammatory hormone? Emerging evidence from reproductive aging models. Ann NY Acad Sci 2005; 1052: 75-9.
79. Suarez C, Díaz-Torga G, Gonzá lez-Iglesias A, Cristina C, Becu-Villalobos D. Upregulation of angiotensin II type 2 receptor expression in estrogen-induced pituitary hyperplasia. Am J Physiol Endocrinol Metab 2004; 286: E786-94. (Pubitemid 38506951)
80. Suzuki S, Brown CM, Dela Cruz CD, Yang E, Bridwell DA, Wise PM. Timing of estrogen therapy after ovariectomy dictates the efficacy of its neuroprotective and antiinflammatory actions. Proc Natl Acad Sci USA 2007; 104: 6013-8. (Pubitemid 47175650)
81. Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, et al. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries, regulation by angiotensin II. Circ Res 2002; 14: 1205-13. (Pubitemid 34786906)
82. Tripanichkul W, Sripanichkulchai K, Finkelstein DI. Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication. Brain Res 2006; 1084: 28-37.
83. Tsuda M, Iwai M, Li JM, Li HS, Min LJ, Ide A, et al. Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension 2005; 45: 545-51. (Pubitemid 40411257)
84. Turgeon JL, Carr MC, Maki PM, Mendelsohn ME, Wise PM. Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: insights from basic science and clinical studies. Endocr Rev 2006; 27: 575-605. (Pubitemid 44582052)
85. Turgeon JL, McDonnell DP, Martin KA, Wise PM. Hormone therapy: physiological complexity belies therapeutic simplicity. Science 2004; 304: 1269-73. (Pubitemid 38697412)
86. Unger T. Inhibiting angiotensin receptors in the brain: possible therapeutic implications. Curr Med Res Opin 2003; 19: 449-51. (Pubitemid 36994451)
87. Ungvari Z, Csiszar A, Kaley G. Vascular inflammation in aging. Herz 2004; 29: 733-40. (Pubitemid 40125707)
88. Vegeto E, Benedusi V, Maggi A. Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenera-tive diseases. Front Neuroendocrinol 2008; 29: 507-19.
89. Villar-Cheda B, Rodríguez-Pallares J, Muño A, Valenzuela R, Guerra MJ, Baltatu OC, Labandeira-Garcia JL. Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: implications for progression of Parkinson's disease. Eur J Neurosci 2010; 32: 1695-706.
90. Villar-Cheda B, Valenzuela R, Rodriguez-Perez AI, Guerra MJ, Labandeira-Garcia JL. Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-hydroxydopamine-induced dopaminergic degeneration. Neurobiol Aging 2012; 33: 204.e1-204.e11.
91. Wu D, Teisman P, Tieu K, Vila M, Jackson-Lewis V, Ischiropoulos H, et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci USA 2003a; 100: 6145-50. (Pubitemid 36576945)
92. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 2002; 22: 1763-71. (Pubitemid 35386294)
93. Wu Z, Zheng W, Sandberg K. Estrogen regulates adrenal angiotensin type 1 receptors by modulating adrenal angiotensin levels. Endocrinology 2003b; 144: 1350-6. (Pubitemid 36428477)
94. Xue B, Johnson AK, Hay M. Sex differences in angiotensin II-induced hypertension. Braz J Med Biol Res 2007a; 40: 727-34. (Pubitemid 46722220)
95. Xue B, Pamidimukkala J, Lubahn DB, Hay M. Estrogen receptor-alpha mediates estrogen protection from angiotensin II-induced hypertension in conscious female mice. Am J Physiol Heart Circ Physiol 2007b; 292: H1770-6. (Pubitemid 46572400)
96. Xue B, Zhao Y, Johnson AK, Hay M. Central estrogen inhibition of angiotensin II-induced hypertension in male mice and the role of reactive oxygen species. Am J Physiol Heart Circ Physiol 2008; 295: H1025-32.
97. Zorad S, Dou J, Benicky J, Hutanu D, Tybitanclova K, Zhou J, Saavedra JM. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARj? Eur J Pharmacol 2006; 552: 112-22. (Pubitemid 44754970)